Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Our original abstract check agrees: practitioner-like metabolic programme, no substantive benefit and cyanide hazards. The175 evaluable/one temporary partial response detail is supplied by a later review in Consensus and by auxiliaryNCIcontext in our check; it is not directly verified in an original trial body. Do not call this an RCT or zero responses. Original PMID7033783. Access: abstract_metadata.
The original1978 abstract retains six responses judged by a blinded oncology panel, while only presumed-success cases were solicited and incomplete records excluded. These observations justify interest without proving a treatment effect or becoming an independent controlled trial. Original PMID683212. Access: abstract_metadata.
Original six-patient abstract confirms low observed toxicity withIVadministration, increased oral cyanide and transient symptoms in one almond-challenged patient. Small route-specific observations cannot prove safety of every IV dose or efficacy. Original PMID7005480. Access: abstract_metadata.
Original pharmacology distinguishes high, briefIVparent plasma levels from very low oral parent levels with cyanide increase. These are parent plasma measurements, not sustained tumour concentration. Culturemg/mL activity cannot be equated to the same human exposure. Original PMID7273266. Access: abstract_metadata.
Original Results verifies HepG2 versusWI38 differentialIC50 and sorafenib synergy atmg/mL concentrations. Unmatched tissue types, cell proliferation and missing whole-organ exposure still limit a human therapeutic window; the positive comparator is retained. Original PMID37726740. Access: full_text_partial.
Original body distinguishes minimal growth effect from1 mg/mLalone from strong sulforaphane-combination effects, and reports no induced apoptosis in those assays. A low dose in that protocol is not verified patient exposure. Original PMID39519581. Access: full_text_partial.
Original magnetic-enzyme Results agree with a restricted delivery benefit and retain inactive targeting controls. AST, CK and LDHincrease despite no obvious organ histology injury. Neither the carrier norenzyme addition is historical free-drug therapy, and limited histology cannot be labeled complete safety. Original PMID32636623. Access: full_text_partial.
Original record and selected Methods/Results were examined: thirty rats in small DMBA groups, topical loaded gel versus blank gel/oral free compound, reduced local carcinoma volume and skin pathology. These results remain positive in their context, but do not measure a human regimen, systemic cyanide margin or complete normal-organ safety. Provider graphics are not republished. Original PMID36355478. Access: full_text_partial.
The original abstract reports release, mucin/flow and H1299 cell activity, then makes a broad protection conclusion. Our original-body access is unavailable, so an independent normal-tissue endpoint was not verified. Its abstract supports a delivery lead, not clinical proof of protection. Original PMID32097740. Access: abstract_metadata.
Original abstract agrees that refusal is important: mortality association becomes nonsignificant after refusal/delay adjustment. This observational attenuation is not randomized mediation proof, not a compound-specific hazard ratio and not evidence that every complementary use causes death. Original PMID30027204. Access: abstract_metadata.
OriginalMethods confirms retrospective primary-treatment refusal, limited age/year/stage matching and exclusion of older patients. The association is clinically relevant but cannot identify laetrile exposure or remove every selection factor. Original PMID22734852. Access: full_text_partial.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.